Bipolar Disorder Pharmacotherapy: Lithium, Valproate, and Atypical Antipsychotics

Lithium: The Reference Standard

Lithium remains the only mood stabilizer with consistent evidence for reducing suicide risk in bipolar disorder, with a meta-analysis by Cipriani et al. (2013) demonstrating a 60% reduction in suicide and deliberate self-harm (OR 0.13, 95% CI 0.03-0.66). For acute mania, lithium achieves response rates of 40-50% as monotherapy, with optimal serum levels of 0.8-1.2 mEq/L. The BALANCE trial (2010) demonstrated superior relapse prevention with lithium plus valproate combination versus valproate monotherapy (HR 0.59, 95% CI 0.42-0.83), though lithium monotherapy was noninferior to the combination.

Monitoring requirements include serum lithium levels every 3-6 months at steady state, renal function (creatinine and eGFR), thyroid function (TSH), and calcium annually. The risk of lithium nephropathy with chronic use (estimated at 1.2% progression to stage 4 CKD over 20 years) must be weighed against its unparalleled anti-suicidal efficacy.

Valproate: Efficacy and Safety Considerations

Valproate (divalproex sodium) is particularly effective for rapid-cycling bipolar disorder and mixed episodes, with response rates of 48-53% in acute mania at trough levels of 85-125 mcg/mL. The CANMAT/ISBD 2018 guidelines recommend valproate as a first-line option for acute mania. However, teratogenicity (10-15% risk of major malformations, including neural tube defects at a rate of 1-2%) makes it absolutely contraindicated in women of childbearing potential without reliable contraception. Weight gain (averaging 5-10 kg) and hepatotoxicity monitoring with LFTs every 6 months are additional considerations.

Atypical Antipsychotics: Expanding the Armamentarium

Quetiapine holds the broadest evidence base across bipolar illness phases. The BOLDER I and II trials demonstrated quetiapine monotherapy (300 mg or 600 mg daily) significantly improved bipolar depression (MADRS reduction of 16.4 versus 12.6 for placebo, p<0.001) with an NNT of 6. Lurasidone (20-120 mg daily) showed comparable efficacy in bipolar depression (PREVAIL 1 and 2 trials) with a more favorable metabolic profile. For acute mania, olanzapine, risperidone, and aripiprazole all demonstrate response rates of 50-65% as monotherapy.